Ingrezza has been available on the market since its initial FDA approval on October 20, 2016. [1]
When Does Ingrezza's Market Exclusivity End?
Ingrezza's primary market exclusivity is tied to its patent protections. According to DrugPatentWatch.com, the earliest patent expiry for Ingrezza is listed as February 27, 2029. [2] However, multiple patents protect the drug, and their expiration dates vary.
What are the Key Patents Protecting Ingrezza?
Ingrezza is protected by several patents. The core patent covering the compound itself has an expiration date of February 27, 2029. [2] There are also patents related to its formulation and methods of use, which may extend exclusivity for specific applications or forms of the drug.
What is the Mechanism of Action for Ingrezza?
Ingrezza (tianeptine sulfate) is a selective agonist of the mu-opioid receptor and an agonist of the delta-opioid receptor. [1] It also has activity at the serotonin transporter, affecting serotonin reuptake. [1] This unique pharmacological profile is believed to contribute to its efficacy in treating conditions like tardive dyskinesia and major depressive disorder.
Who Manufactures Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences. [1]
How Does Ingrezza Compare to Other Treatments?
For tardive dyskinesia, Ingrezza was the first VMAT2 inhibitor approved by the FDA specifically for this condition. [1] Before Ingrezza, treatment options for tardive dyskinesia were limited. For major depressive disorder, Ingrezza is used as an adjunctive treatment, meaning it is taken in addition to standard antidepressant medications. [1]
What are the Approved Indications for Ingrezza?
Ingrezza is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with tardive dyskinesia and for the treatment of adults with major depressive disorder. [1]
What Clinical Data Supports Ingrezza's Efficacy?
The FDA approval of Ingrezza was based on clinical trials demonstrating its effectiveness in reducing involuntary movements associated with tardive dyskinesia. [1] For major depressive disorder, studies showed that Ingrezza improved depressive symptoms when used as an add-on therapy. [1]
What Are the Potential Side Effects of Ingrezza?
Common side effects of Ingrezza include somnolence and potentially QT interval prolongation. [1] Patients are advised to discuss any concerns about side effects with their healthcare providers.
When Did Ingrezza Receive FDA Approval?
Ingrezza received its first FDA approval on October 20, 2016. [1]
*
**Sources:
[1] https://www.ingrezza.com/
[2] https://drugpatentwatch.com/